<DOC>
	<DOCNO>NCT02987062</DOCNO>
	<brief_summary>According current guideline non-valvular atrial fibrillation treatment , first line drug non-vitamin K oral anticoagulant ( NOACs ) , preferred vitamin K antagonist ( VKAs ) . However , clearly confirm , success NOACs approval trial ( ROCKET-AF ( rivaroxaban ) , RE-LY ( dabigatran ) ARISTOTLE ( apixaban ) reflect real-life clinical practice . The aim study assess treatment AF patient oral anticoagulant ( OACs ) academic district hospital , regard inclusion/exclusion criterion use clinical trial .</brief_summary>
	<brief_title>MultiCenter expeRience AFib Patients Treated With OAC ( CRAFT )</brief_title>
	<detailed_description>Atrial fibrillation ( AF ) common arrhythmia associate increase cardiovascular morbidity mortality . An integral element management patient AF anticoagulation prevent thromboembolic event . Non-vitamin K oral anticoagulant vitamin K antagonist two main drug group use treatment . Primary objective study ass treatment AF patient OACs ( frequency prescription VKAs v NOACs ) , compare clinical characteristic real-life AF patient population include randomized clinical trial ( ROCKET-AF , RE-LY ARISTOTLE ) population gather university department district hospital . Secondary objective study ass long-term outcome patient AF treat OACs . The CRAFT ( MultiCenter expeRience AFib patient Treated OAC ) multicenter retrospective analysis hospital record patient AF manage First Department Cardiology Medical University Warsaw John Paul II Western Hospital Grodzisk Mazowiecki . Gathered data include demographic , type AF ( valvular non-valvular , well paroxysmal , persistent permanent ) , medical history , baseline characteristic ( i.e . blood pressure ) , laboratory investigation ( blood test , include renal hepatic function ) , echocardiographic parameter concomitant medication . Data collect moment patient 's discharge . Each patient evaluate regard common new scale assess risk thromboembolic ( CHA2DS2-VASc ) bleeding ( HAS-BLED , HEMORR2HAGES , modifiable non-modifiable risk factor bleed anticoagulated patient base current guideline AF treatment ) event , well SAMeTT2R2 score predict quality treatment OACs .</detailed_description>
	<mesh_term>Atrial Fibrillation</mesh_term>
	<mesh_term>Rivaroxaban</mesh_term>
	<mesh_term>Acenocoumarol</mesh_term>
	<criteria>Inclusion criterion : paroxysmal , persistent , longstanding persistent permanent AF valvular nonvalvular AF treatment OACs ( apixaban , dabigatran , rivaroxaban , acenocoumarol , warfarin ) Exclusion criterion : lack OAC hospital discharge</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Atrial Fibrillation</keyword>
	<keyword>Non-vitamin K Oral Anticoagulants</keyword>
	<keyword>Vitamin K Antagonists</keyword>
	<keyword>ROCKET-AF</keyword>
	<keyword>RE-LY</keyword>
	<keyword>ARISTOTLE</keyword>
</DOC>